GAITHERSBURG, Md. (EGMN) - In a near-unanimous vote, a Food and Drug Administration advisory panel recommended that the approval of bevacizumab as a first-line treatment for patients with metastatic breast cancer be withdrawn because follow-up studies failed to confirm progression-free survival benefits in this population.The FDA had granted an "accelerated" approval to bevacizumab (Avastin) in combination with paclitaxel (Taxol) in February 2008 for the treatment of patients who have not received...